Attention study in sickle cell disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a medication to see if it can improve attention in people with sickle cell disease. It may help with thinking and focus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have sickle cell disease and no major memory or thinking problems.
- You do not smoke.
- You do not have a neurological condition like stroke or epilepsy.
- You are medically able to take the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a daily supplement of beta-hydroxybutyrate (a ketone body) can help support brain health in older adults who are still thinking clearly. It compares the supplement to a placebo over several months, and checks changes in brain function and energy use.
This trial tests whether a computer-based “attention control” training program can improve attention and daily functioning in children with sickle cell disease. To join, you must meet certain criteria and also pass an initial attention screening test during the study.
This trial tests if a medication called methylphenidate can help children with sickle cell disease who have trouble with attention, focus, or executive function. It aims to see if it can improve daily life and school performance.
This trial is testing a digital program to help improve working memory (the ability to hold and use information in your mind) for children with sickle cell disease. If you join, you'll use a computer-based training program at home and researchers will see if it works and is easy to use.
This trial tests a program to help maintain or improve memory and thinking skills in older adults. You may join if you are 60-89, speak English, and live at home or in an assisted-living facility.
This Phase 1 study tests minocycline (an antibiotic) to see how it affects brain or thinking outcomes in adults with certain types of sickle cell disease. It may help researchers learn whether the medicine is safe and could improve neurocognitive function in this specific group.
Hear when a new Subjective Cognitive Decline trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.